MaxCyte

MaxCyte is a leading supplier of cell engineering platform technology. We provide our patented high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy (including gene editing and immuno-oncology). With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and address development and commercialization challenges. Leveraging its advanced cell engineering technology, MaxCyte is driving the next generation of cell-based therapies, particularly in gene editing and immuno-oncology. The company’s technology is adopted by leading drug developers worldwide, including the top ten global biopharmaceutical companies. Currently, MaxCyte has licensed over 140 cell therapy programs, with more than 100 receiving clinical approval, and has granted 13 strategic platform licenses to leading cell therapy developers.